Ferrer, AL, Belinchón, I, Serra, MC, Clua, MG, Mate, AR, Suárez, BP, Alarcón, SS, de la Cueva, P. REVIEW OF PATIENT DECISION AIDS FOR PSORIASIS. VALUE IN HEALTH. 2025; 28(12)DOI:. PMID:. IF:6.000(Q1/1D).

Ferrer, AL, Belinchón, I, Serra, MC, Martínez, LE, Mate, AR, Suárez, BP, Alarcón, SS, de la Cueva, P. UNDERSTANDING PATIENT PRIORITIES IN PSORIASIS TREATMENT: A REVIEW OF KEY DECISION-MAKING DRIVERS. VALUE IN HEALTH. 2025; 28(12)DOI:. PMID:. IF:6.000(Q1/1D).

Strober, B, Puig, L, Lebwohl, MG, Lakshminarasimhan, B, Khan, SA, Pillai, N, Kappelhoff, B, Weatherill, A, Warren, RB. HIGHER MORTALITY FOR GENERALIZED PUSTULAR PSORIASIS COMPARED WITH PLAQUE PSORIASIS HIGHLIGHTS THE NEED FOR IMPROVED TREATMENTS: INSIGHTS FROM A META-ANALYSIS. VALUE IN HEALTH. 2025; 28(12)DOI:. PMID:. IF:6.000(Q1/1D).

Fernández, CPH, Borrego, L, Arnau, AMG, Sánchez, TS, Carrillo, JMC, Ninet, VZ, Baldrich, ES, Miquel, FJM, Salvador, JFS, Guijarro, SC, Gilo, AS, García, PM, Triviño, FN, Romero, FT, Serna, MR, Ninot, GM, González, IR, de la Fuente, EG, Nieto, MAP, Guillén, PSP, Pérez, JS, Rodríguez, JJP, Ortega, MEG, Pérez, RG, Doval, IG, Descalzo, MAG. Should Hydroxyisohexyl 3-Cyclohexene Carboxaldehyde (Lyral®) still be part of the Baseline Series?. Actas Dermo-Sifiliograficas. 2025; 116(10)DOI:10.1016/j.ad.2024.10.063. PMID:40024601. IF:(Q/D).

Mateu-Arrom, L, Martin, R, Expósito-Serrano, V, Alvarez-Abella, A, Serra-Baldrich, E, Spertino, J. Azathioprine for the Treatment of Chronic Spontaneous Urticaria Refractory to Antihistamines, Omalizumab, and Ciclosporin: A Case Series. Actas Dermo-Sifiliograficas. 2025; 116(8)DOI:10.1016/j.ad.2025.05.022. PMID:40480489. IF:(Q/D).

Feldman, SR, Sanz, LP, Girolomoni, G, Jo, SJ, Jung, H, Jung, J. Similarity of efficacy of SB17 to reference ustekinumab for moderate-to-severe psoriasis through 12 weeks in different demographic and comorbidity subgroups. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2025; 93(3)DOI:. PMID:. IF:11.800(Q1/1D).